Search for a trial

Urolastic® versus Bulkamid® in treatment of female stress incontinence: randomized controlled trial.

Subjective cure of urinary stress incontinence at 12 months after intervention and comparison of a new bulking agent Urolastic ® with Bulkamid® in the treatment of stress urinary incontinence. Our hypothesis: based on our study and literature…

INJECTABLE BULKING AGENT FOR MALE URINARY INCONTINENCE TREATMENT: A MULTI-CENTRE EFFECTIVENESS AND SAFETY PILOT STUDY

Hypothesis: Opsys will improve mild incontinence based on urine loss per 24 h measured by 24 h pad test.The main objective of this study is to test the effectiveness of Opsys in a group of selected subjects with minimal to mild (less than 30 g per…

The European Study of Altis® Single Incision Sling System for Female Stress Urinary Incontinence;A prospective, post-market, single arm, multicenter comparing baseline data to the 12 and 36 month data in 136 patients with stress urinary incontinence

Primary goal:The cure at 12 monthsSecondary goals:1. Cough Stress Test (HST): objective endpoint2. Question 3 of the UDI-6 questionnaire: subjective endpoint3. Primary endpoint at 6 weeks, 6 months, and 36 months 24maanden4. Reduction of urine loss…

Levobupivacaine for pediatric caudal block. Comparison of three different dose in children undergoing hypospadia repair: a double-blinded randomised study

To determine the best doses-respons of levobupivacaine for postoperatief analgesia after caudal anesthesia for hypospadia repair.

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

To determine if treatment with infigratinib improves centrally reviewed disease-free survival (DFS) compared with placebo treatment in subjects with invasive urothelial carcinoma with susceptible FGFR3 alterations after nephroureterectomy, distal…